🧠 Watchlist Winners: Copy Legendary Investors' Portfolios in One ClickCOPY FOR FREE

Axsome Therapeutics Inc (19X)

TradeGate
Currency in EUR
Disclaimer
83.80
+1.56(+1.90%)
Closed
Fair Value
Day's Range
82.1683.80
52 wk Range
52.4093.00
Bid/Ask
84.00 / 84.98
Prev. Close
82.24
Open
82.16
Day's Range
82.16-83.8
52 wk Range
52.4-93
Volume
172
Average Vol. (3m)
440
1-Year Change
18.7%
Fair Value
Unlock
Fair Value Upside
Unlock
19X Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
125.24
Upside
+33.70%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Axsome Therapeutics Inc Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Employees
502

Compare 19X to Peers and Sector

Metrics to compare
19X
Peers
Sector
Relationship
P/E Ratio
0.0x−3.6x−0.6x
PEG Ratio
0.000.000.00
Price / Book
0.0x0.5x2.6x
Price / LTM Sales
0.0x0.8x3.1x
Upside (Analyst Target)
0.0%133.4%55.7%
Fair Value Upside
Unlock22.3%6.9%Unlock

People Also Watch

66.730
VKTX
+6.24%
29.830
ASTS
+11.35%
85.55
VST
+6.31%
457.16
SMCI
+3.40%
69.51
DXCM
+1.00%

FAQ

What Is the Axsome Therapeutics Inc (19X) Stock Price Today?

The Axsome Therapeutics Inc stock price today is 83.80

What Stock Exchange Does Axsome Therapeutics Inc Trade On?

Axsome Therapeutics Inc is listed and trades on the TradeGate stock exchange.

What Is the Stock Symbol for Axsome Therapeutics Inc?

The stock symbol for Axsome Therapeutics Inc is "19X."

What Is the Axsome Therapeutics Inc Market Cap?

As of today, Axsome Therapeutics Inc market cap is 4.06B.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.